S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

MediWound Stock Forecast, Price & News

-0.05 (-2.72%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
40,266 shs
Average Volume
86,572 shs
Market Capitalization
$59.32 million
P/E Ratio
Dividend Yield
Price Target

MediWound Stock Forecast (MarketRank)

Analyst Rating
3.00 Rating Score
300.4% Upside
$7.17 Price Target
Short Interest
0.18% of Float Sold Short
Dividend Strength
News Sentiment
0.72mentions of MediWound in the last 14 days
Based on 7 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.38) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.59 out of 5 stars

Medical Sector

921st out of 1,428 stocks

Medicinals & Botanicals Industry

8th out of 23 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MediWound logo

About MediWound (NASDAQ:MDWD) Stock

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MDWD Stock News Headlines

StockNews.com Initiates Coverage on MediWound (NASDAQ:MDWD)
Protect Your Trading Account With Options!
This might be the opposite of what you’ve heard, but the real risk in the market now lies with stock trading… “Options Trading Made Easy” by expert Chuck Hughes will show you how the nature of options trading gives you the chance to profit no matter which way the market trends! Get the e-book today!
MediWound (NASDAQ:MDWD) Coverage Initiated at StockNews.com
Protect Your Trading Account With Options!
This might be the opposite of what you’ve heard, but the real risk in the market now lies with stock trading… “Options Trading Made Easy” by expert Chuck Hughes will show you how the nature of options trading gives you the chance to profit no matter which way the market trends! Get the e-book today!
MediWound Announces CEO Transition - GlobeNewswire
MediWound Announces CEO Transition
See More Headlines

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-13.55 million
Pretax Margin


Sales & Book Value

Annual Sales
$23.76 million
Book Value
($0.17) per share


Free Float
Market Cap
$59.32 million
Not Optionable

MediWound Frequently Asked Questions

Should I buy or sell MediWound stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound
or view top-rated stocks.

What is MediWound's stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price targets for MediWound's shares. Their MDWD stock forecasts range from $6.50 to $8.00. On average, they expect MediWound's share price to reach $7.17 in the next year. This suggests a possible upside of 300.4% from the stock's current price.
View analysts' price targets for MediWound
or view top-rated stocks among Wall Street analysts.

How has MediWound's stock performed in 2022?

MediWound's stock was trading at $2.36 at the start of the year. Since then, MDWD stock has decreased by 24.2% and is now trading at $1.79.
View the best growth stocks for 2022 here

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for MediWound

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. The biopharmaceutical company earned $4.41 million during the quarter, compared to analyst estimates of $4.35 million. MediWound had a negative trailing twelve-month return on equity of 3,540.43% and a negative net margin of 64.01%. During the same period in the prior year, the firm posted ($0.10) earnings per share.
View MediWound's earnings history

Who are MediWound's key executives?

MediWound's management team includes the following people:
  • Mr. Sharon Malka CPA, MBA, Chief Exec. Officer (Age 50, Pay $497k)
  • Prof. Lior Rosenberg M.D., Co-Founder & Chief Medical Technology Officer (Age 76, Pay $398k)
  • Mr. Boaz Gur-Lavie CPA, M.B.A., Chief Financial Officer (Age 48, Pay $309k)
  • Mr. Yaron Meyer Adv., Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $240k)
  • Dr. Ety Klinger, Chief R&D Officer (Age 60, Pay $344k)
  • Mr. Stephen T. Wills CPA, CPA, MST, Exec. Chairman (Age 65)

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $1.79.

How much money does MediWound make?

MediWound (NASDAQ:MDWD) has a market capitalization of $59.32 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13.55 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 77 workers across the globe.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for MediWound is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.

This page (NASDAQ:MDWD) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.